GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (BSP:A1SN34) » Definitions » Deferred Tax

Ascendis Pharma A/S (BSP:A1SN34) Deferred Tax : R$46 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma A/S Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Ascendis Pharma A/S's change in deferred tax for the three months ended in Mar. 2024 was R$14 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2024 was R$46 Mil.

Ascendis Pharma A/S Deferred Tax Historical Data

The historical data trend for Ascendis Pharma A/S's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Deferred Tax Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.07 -1.37 -2.35 29.88 39.02

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.23 -2.26 3.40 30.94 13.58

Ascendis Pharma A/S Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$46 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S Deferred Tax Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (BSP:A1SN34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (BSP:A1SN34) » Definitions » Deferred Tax
Comparable Companies
ABCZF IMVT HALO PCVX APLS BBIO CERE MRTX KRTX ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ASND:USA ASND:Mexico A71:Germany
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Website
http://www.ascendispharma.com
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (BSP:A1SN34) Headlines

No Headlines